![The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000361-mmc7.jpg)
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect
![Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease | SpringerLink Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11033-021-06512-9/MediaObjects/11033_2021_6512_Figa_HTML.png)
Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease | SpringerLink
![The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000361-ga1.jpg)
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect
![The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000361-gr2.jpg)
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect
![The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Falzrt179/MediaObjects/13195_2013_Article_153_Fig4_HTML.jpg)
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text
![The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000361-mmc6.jpg)
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect
![PDF) A Geroprotector J147 Targeting Mitochondrial Dysfunction in the Aging Brain: A Novel Therapeutic Approach for Alzheimer's Disease PDF) A Geroprotector J147 Targeting Mitochondrial Dysfunction in the Aging Brain: A Novel Therapeutic Approach for Alzheimer's Disease](https://i1.rgstatic.net/publication/331815850_A_Geroprotector_J147_Targeting_Mitochondrial_Dysfunction_in_the_Aging_Brain_A_Novel_Therapeutic_Approach_for_Alzheimer's_Disease/links/5fd1e88392851c00f862771c/largepreview.png)
PDF) A Geroprotector J147 Targeting Mitochondrial Dysfunction in the Aging Brain: A Novel Therapeutic Approach for Alzheimer's Disease
![The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000361-gr1.jpg)
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver - ScienceDirect
![Alzheimer's disease drug development pipeline: 2019 - Cummings - 2019 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library Alzheimer's disease drug development pipeline: 2019 - Cummings - 2019 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library](https://alz-journals.onlinelibrary.wiley.com/cms/asset/9988a8c6-b33c-44e4-99ef-896006448a17/trc2jtrci201905008-fig-0001-m.jpg)
Alzheimer's disease drug development pipeline: 2019 - Cummings - 2019 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
![The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Falzrt179/MediaObjects/13195_2013_Article_153_Fig3_HTML.jpg)
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice | Alzheimer's Research & Therapy | Full Text
![J147 and CMS121 preferentially reverse age-associated protein level... | Download Scientific Diagram J147 and CMS121 preferentially reverse age-associated protein level... | Download Scientific Diagram](https://www.researchgate.net/profile/Devin-Kepchia/publication/349102002/figure/fig3/AS:998436023312385@1615057106319/J147-and-CMS121-preferentially-reverse-age-associated-protein-level-alterations-in-the.png)